SBIR Phase I: A Novel Optical Biosensor for Rapid Clinical Diagnostics

这一小型企业创新研究(SBIR)第一阶段研究项目将展示直接检测和量化P53抗体作为生物液中其他大分子的模型的可行性，而不需要使用任何报告分子，方法是在独特的、获得专利的全息干涉仪中使用生物传感元件。本发明寻求将当前验证的气相检测系统的检测能力扩展到液体介质中的生物分子。在液体系统中的应用是下一个合乎逻辑的步骤，基于该仪器在检测低于ppm级别的空气中的化学物质方面所表现出的灵敏度和速度。所提出的创新的实现将提供低成本、快速、护理点检测以及血清和其他生物液中生物标记物的量化的好处，否则需要昂贵的、劳动密集型的多步骤检测技术。

This Small Business Innovation Research (SBIR) Phase I research project will demonstrate the feasibility of direct detection and quantification of p53 antibodies as a model for other macromolecules in biological fluids without using any reporter molecules through the use of bio-sensing elements in a unique, patented holographic interferometer. The present innovation seeks to extend detection capabilities of the currently validated gas phase detection system to biological molecules in liquid media. Application in liquid systems is the next logical step based on the instruments demonstrated sensitivity and speed in detection of airborne chemicals at sub ppm levels. Realization of the proposed innovation will provide the benefits of low cost, fast, point of care detection and quantification of biomarkers in sera and other biological fluids which otherwise require expensive, labor-intensive, multiple step detection techniques.